{"public_id":"co_afedb8596f96002a387dd2c987e64c3b","status":"active","merged_into_public_id":null,"resolved_public_id":"co_afedb8596f96002a387dd2c987e64c3b","name":"heterologous ChAdOx1/BNT162b2 vaccination","description":"A mixed COVID-19 vaccination strategy in which two ChAdOx1 primary doses are followed by a BNT162b2 booster, designated ChAd/ChAd/BNT in this study.","aliases":["ChAd/ChAd/BNT","heterologous vaccination schedule"],"types":["vaccination strategy"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":252457006,"title":"An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results","citation_count":2,"url":"https://sah.borca.ai/papers/252457006"}],"claims":[{"public_id":"cl_bad18e713ec7982ecca07263f7ebae64","text":"At 21 days after BNT162b2 booster administration in 48 ChAd/ChAd/BNT-vaccinated participants, all subjects achieved reactive/positive anti-SARS-CoV-2 IgG titers.","corpus_id":252457006,"url":"https://sah.borca.ai/claims/cl_bad18e713ec7982ecca07263f7ebae64"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_afedb8596f96002a387dd2c987e64c3b","url":"https://sah.borca.ai/concepts/co_afedb8596f96002a387dd2c987e64c3b"}